Krensavage Asset Management LLC Buys 49,873 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Krensavage Asset Management LLC raised its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 49.7% during the fourth quarter, HoldingsChannel reports. The firm owned 150,205 shares of the biotechnology company’s stock after buying an additional 49,873 shares during the period. United Therapeutics comprises about 28.6% of Krensavage Asset Management LLC’s investment portfolio, making the stock its biggest holding. Krensavage Asset Management LLC’s holdings in United Therapeutics were worth $52,998,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the fourth quarter worth $25,000. Dunhill Financial LLC lifted its holdings in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 50 shares during the period. State of Wyoming acquired a new position in United Therapeutics during the fourth quarter worth $62,000. Millstone Evans Group LLC purchased a new position in United Therapeutics in the fourth quarter worth $67,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lowered their price target on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. Bank of America upgraded United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price on the stock in a research report on Monday, April 21st. Morgan Stanley upped their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a report on Thursday, May 1st. HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $392.00.

United Therapeutics Trading Down 0.0%

Shares of NASDAQ:UTHR opened at $305.31 on Tuesday. The firm has a market cap of $13.77 billion, a price-to-earnings ratio of 13.41, a PEG ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a 12-month low of $264.33 and a 12-month high of $417.82. The stock’s 50-day moving average price is $299.92 and its two-hundred day moving average price is $339.72.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.17 earnings per share. As a group, research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. This trade represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $929,678.52. The trade was a 79.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 55,500 shares of company stock valued at $17,054,780 in the last ninety days. Company insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.